Haemato AG Claim profile
ISIN: DE000A289VV1 | Ticker: HAEK | LEI: 529900Q3CGRYVCW7E34
HAEMATO has been committed for over 15 years as a pharmaceutical manufacturer and wholesaler to actively contributing to cost reduction in the healthcare sector, so that every patient can benefit from the latest therapies and treatment concepts, even if these are often very expensive. In addition, the Group focuses on the development and distribution of own brands in the Lifestyle & Aesthetics segment.
HAEMATO covers chronic diseases and high-priced therapies in particular with its own product portfolio. The focus is on the five therapeutic areas of HIV/AIDS, neurology, oncology, rheumatology and ophthalmology. These therapeutic areas include innovative, patent-protected drugs as well as biosimilars and generics. The product portfolio is rounded off with narcotics, which also include cannabis products.
1993
Served areaWorldwide
HeadquartersLilienthalstraße 3a, 12529 Schoenefeld – Germany
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ENG | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | ENG | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
5,230,000
IPODec. 5, 2005
Stock exchange(s)Frankfurt Stock Exchange
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.